Mitchell Kaye
Director/Board Member at AEOLUS PHARMACEUTICALS, INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Cavalier | M | 54 | 20 years | |
John McManus | M | 60 | 19 years | |
Adrian Hinton | M | 72 | 5 years | |
Jeffrey Scott | M | 67 | 11 years | |
John Clerici | M | 54 | 11 years | |
Amit Kumar | M | 59 | 20 years | |
Chris Rallis | M | 70 | 20 years | |
John Farah | M | 72 | 19 years | |
Jane Ryan | M | 65 | 4 years | |
Aaron Weaver | M | 43 | 4 years | |
Nancy Kaye | F | - |
MedClaims Liaison LLC
MedClaims Liaison LLC Insurance Brokers/ServicesFinance MedClaims Liaison LLC provides healthcare reimbursement services. The private company is based in Ridgefield, CT. The company was founded in 2009 by Mitchell D. Kaye, Nancy Kaye. | 15 years |
Peter Davies | M | 43 | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Russell Skibsted | M | 65 | 3 years | |
Brian J. Day | M | 63 | 23 years | |
Connor Bernstein | M | 37 | 2 years | |
Peter David Suzdak | M | 65 | 9 years | |
Deborah Rathjen | M | - | 19 years | |
Tim Lankes | M | 64 |
Health Revenue Assurance Holdings, Inc.
Health Revenue Assurance Holdings, Inc. Services to the Health IndustryHealth Services Health Revenue Assurance Holdings, Inc. engages in the provision of revenue cycle services for healthcare providers. It offers revenue cycle data analysis, contract and outsourced coding, International Classification Disease-10 (ICD) education, and transition services. The company was founded on December 13, 2010 and is headquartered in New York, NY. | - |
Leanne Kelly | F | 47 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 7 years |
Stephen Birrell | M | - | 6 years | |
Jack Moschakis | M | - | 6 years | |
Jennifer Lou Armstrong-Owen | F | 54 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 11 years |
Michael E. Lewis | M | 72 | 9 years | |
Joseph J. Krivulka | M | 73 | 9 years | |
John L. Armstrong | M | 80 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 4 years |
Suzanne Irwin | F | - | 2 years | |
Steven Lydeamore | M | 56 | 1 years | |
Dennis Veasman | M | - |
Health Revenue Assurance Holdings, Inc.
Health Revenue Assurance Holdings, Inc. Services to the Health IndustryHealth Services Health Revenue Assurance Holdings, Inc. engages in the provision of revenue cycle services for healthcare providers. It offers revenue cycle data analysis, contract and outsourced coding, International Classification Disease-10 (ICD) education, and transition services. The company was founded on December 13, 2010 and is headquartered in New York, NY. | - |
Dean Boyer | M | - |
Health Revenue Assurance Holdings, Inc.
Health Revenue Assurance Holdings, Inc. Services to the Health IndustryHealth Services Health Revenue Assurance Holdings, Inc. engages in the provision of revenue cycle services for healthcare providers. It offers revenue cycle data analysis, contract and outsourced coding, International Classification Disease-10 (ICD) education, and transition services. The company was founded on December 13, 2010 and is headquartered in New York, NY. | - |
Michael Gallagher | M | - |
Health Revenue Assurance Holdings, Inc.
Health Revenue Assurance Holdings, Inc. Services to the Health IndustryHealth Services Health Revenue Assurance Holdings, Inc. engages in the provision of revenue cycle services for healthcare providers. It offers revenue cycle data analysis, contract and outsourced coding, International Classification Disease-10 (ICD) education, and transition services. The company was founded on December 13, 2010 and is headquartered in New York, NY. | - |
Robert Gundel | M | - |
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | 1 years |
Jason S. Simmers | M | - |
Navigant Capital Advisors LLC
Navigant Capital Advisors LLC Investment ManagersFinance Navigant Capital Advisors LLC provides investment banking services. It offers fairness opinion, mergers and acquisition, private placement, due diligence, divestiture, leveraged recapitalization and refinancing, debt and equity underwriting and business turnaround advisory services. The company is headquartered in Chicago, IL. | 3 years |
Dan Andersen | M | - |
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | - |
Brian McDaid | M | - |
Navigant Capital Advisors LLC
Navigant Capital Advisors LLC Investment ManagersFinance Navigant Capital Advisors LLC provides investment banking services. It offers fairness opinion, mergers and acquisition, private placement, due diligence, divestiture, leveraged recapitalization and refinancing, debt and equity underwriting and business turnaround advisory services. The company is headquartered in Chicago, IL. | - |
Henry R. Wolfe | M | 66 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 4 years |
Robert Frank Shapiro | M | 90 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 13 years |
Daniel B. Rubinstein | M | - |
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | - |
David Eric Kroin | M | 48 |
Health Revenue Assurance Holdings, Inc.
Health Revenue Assurance Holdings, Inc. Services to the Health IndustryHealth Services Health Revenue Assurance Holdings, Inc. engages in the provision of revenue cycle services for healthcare providers. It offers revenue cycle data analysis, contract and outsourced coding, International Classification Disease-10 (ICD) education, and transition services. The company was founded on December 13, 2010 and is headquartered in New York, NY. | 1 years |
Daniel S. Pereira | M | - |
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | - |
Zola P. Horovitz | M | 89 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 14 years |
Jonathan Fassberg | M | - |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | - |
Jennifer Bilotti | F | - |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | - |
Peter J. Turner | M | 74 | 4 years | |
Srinivas Rao | M | 55 | 1 years | |
Jon Berger | M | 65 |
Navigant Capital Advisors LLC
Navigant Capital Advisors LLC Investment ManagersFinance Navigant Capital Advisors LLC provides investment banking services. It offers fairness opinion, mergers and acquisition, private placement, due diligence, divestiture, leveraged recapitalization and refinancing, debt and equity underwriting and business turnaround advisory services. The company is headquartered in Chicago, IL. | 6 years |
Carl Gordon | M | 59 |
Arius Research, Inc.
Arius Research, Inc. BiotechnologyHealth Technology Arius Research, Inc. develops anti-cancer antibodies. The company is headquartered in Toronto, Canada. | 3 years |
Greg Fortunoff | M | 54 |
Xmark Fund Ltd.
| 1 years |
Osagie Imasogie | M | 62 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 5 years |
Paul Wotton | M | 63 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | 1 years |
Angeline K. Shashlo | F | - |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | - |
Barry A. Berkowitz | M | - |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 34 | 66.67% |
Australia | 12 | 23.53% |
Canada | 5 | 9.80% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mitchell Kaye
- Personal Network